Significance of CA19-9 in Predicting the Prognosis of Urothelial Carcinoma: A Hospital Based Study from Nepal

  • Jha, Dipendra Kumar (Department of Biochemistry, Nepalese Army Institute of Health Sciences) ;
  • Mittal, Ankush (Department of Biochemistry, Nepalese Army Institute of Health Sciences) ;
  • Gupta, Satrudhan Pd (Department of Biochemistry, Nepalese Army Institute of Health Sciences) ;
  • Sathian, Brijesh (Department of Community Medicine, Manipal College of Medical Sciences)
  • Published : 2013.07.30


Background: The present study was undertaken to establish any correlation of elevated levels of CA19-9 with tumor stage or grade of urothelial carcinoma. Materials and Methods: This hospital based study was carried out in the Department of Biochemistry of Nepalese Army Institute of Health Sciences between $1^{st}$ July 2012 and $31^{st}$ December 2012. Approval for the study was obtained from the institutional research ethical committee. CA19-9 was assayed with an ELISA reader for all cases and expressed in U/ml with 37U/ml taken as the cut-off upper value for normal. Results: Out of 20 cases enrolled, 15 were of urothelial carcinoma and the remaining 5 were controls. There was marked difference between the mean values of CA19-9 in cases $40.2{\pm}19.3U/ml$ of urothelial carcinoma and controls $7.98{\pm}7.34U/ml$. The number of cases in Ta, TI, T2, T3, T4 stages of urothelial carcinoma were 2, 6, 3, 3, 1 respectively. The percentage rise in CA19-9 was less with low grade tumors (22.2%) when compared with high grade tumors (66.6%) (p value $0.001^*$). The percentage of rise in CA19-9 for muscle invasive tumors was very high when compared to superficial tumors. Similarly, the percentage of rise in CA19-9 for metastatic disease was very high when compared to non-metastatic disease and it was found statistically significant (p value $0.001^*$). Conclusion: Serum CA19-9 levels predicts the prognosis of urothelial carcinoma as it is almost invariably raised in tumors having metastatic spread.


CA 19-9;urothelial carcinoma;prognosis;Nepal


  1. Badar F, Sattar A, Meerza F, et al(2009). Carcinoma of the urinary bladder in a tertiary care setting in a developing country. Asian Pac J Cancer Prev, 10, 449-52.
  2. Bastos Oreiro M, Lopez Rodriguez M, Monedero Martin MC, et al (2008). Elevation of CA 19.9 in urothelial bladder cancer. Med Clin (Barc), 130, 319.
  3. Epstein JI, Amin MB, Reuter VR, et al (1998). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am J Surg Pathol, 22, 1435-48.
  4. Hegele A, Mecklenburg V, Varga Z, et al (2010). CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings. Anticancer Res, 30, 5195-200.
  5. Herberman RB (1977). Immunologic tests in diagnosis of cancer. Am J Clin Pathol, 68, 688-98.
  6. Kikuchi H (2004). Tumor markers of urinary tract carcinoma. Rinsho Byori, 52, 371-80.
  7. Kong CH, Singam P, Hong GE, et al (2010). Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev, 11, 149-52.
  8. Pall M, Iqbal J, Singh SK, et al (2012). CA 19-9 as a serum marker in urothelial carcinoma. Urol Ann, 4, 98-101.
  9. Salehi A, Khezri AA, Malekmakan L, et al (2011). Epidemiologic status of bladder cancer in Shiraz, southern Iran. Asian Pac J Cancer Prev, 12, 1323-7.
  10. Supit W, Mochtar CA, Sugiono M (2011). Survival of patients with transitional cell carcinoma of the urinary bladder in indonesia: a single institution review. Asian Pac J Cancer Prev, 12, 549-53.
  11. Terris MK, Villers A, Freiha FS (1990). Transrectal ultrasound appearance of transitional cell carcinoma involving the prostate. J Urol, 143, 952-6.
  12. Washino S, Hirai M, Matsuzaki A, et al (2011). Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma. Urol Int, 87, 420-8.